Introduction
============

Osteosarcoma (OS) is one of the most common malignant bone tumors and occurs predominantly in children and adolescents [@B1]. Because of its highly malignant and invasive nature, the metastasis of OS often occurs early in patients and, thus, the prognosis is poor [@B2]. Although some patients benefit from surgery and chemotherapy, the 5-year survival rate of OS is still lower than 50% [@B3]. Therefore, it is an urgent problem to clarify the pathology and the molecular mechanism of OS. Previous research have indicated that the process of OS development is complicated and may be influenced by multiple factors [@B4]-[@B5]. Only a portion of people who are exposed to the same environmental factors will develop OS, suggesting that genetic factors may contribute to the carcinogenesis of OS. Therefore, it is necessary to find the genes responsible for susceptibility to OS.

Interleukin-33 (IL-33) was found to be predominantly expressed in the nuclei of stromal cells and activated myeloid cells. Previous studies have confirmed that IL-33 plays an important regulatory role in many physiological and pathological conditions, such as tissue repair, autoimmune diseases and cancer, and it is also considered to be a damage-associated molecular pattern (DAMP) molecule [@B6]. IL-33 is a cytokine member of the IL-1 family, which includes IL-18 and IL-1 [@B7]. Previous studies have shown that high levels of both IL-1α and IL-18 have a positive effect on suppressing the metastasis of OS [@B8]-[@B9]. Additionally, it has been found that the expression of IL-33 in tumor cells can enhance immunogenicity and also promote type 1 antitumor immune responses via CD8+ T cells and NK cells [@B10]-[@B11]. Studies have shown that many cancers can cause an increase in serum IL-33 levels, such as gastric cancer, hepatocellular carcinoma, and lung cancer [@B12]-[@B15]. Moreover, IL-33 is an inhibitor of bone reabsorption that blocks osteoclastic activity in *in vitro* experiments [@B16]; *in vivo*, researchers have also shown that IL-33 can have anti-osteoclastogenic effects, reducing osteoclast formation and activity by inducing their apoptosis in mice [@B17]. Taken together, these studies suggest that IL-33 may be important to the occurrence and development of OS.

A recent genome-wide association study (GWAS) involving 632 OS patients, including 523 European patients and 109 from Brazilian patients, produced highly significant association of GLDC/IL33 locus at 9p24.1 with the risk of OS. Using publicly available data, Koster et al. found that the OS susceptible single nucleotide polymorphism (SNP) in GLDC/IL33 locus associated with low expression of IL-33, which was also significantly correlated with poor survival in OS patients [@B18]. This result suggested that IL-33 might play some roles in the pathogenesis of OS. However, to date, only one report correlating IL-33 with OS is available. Importantly, the study only evaluated OS patients of European and Brazilian descent. Given that different ethnic populations may exhibit genetic heterogeneity of OS, there is a need to confirm these findings with additional samples from different populations. Therefore, in the present study, we aimed to determine whether IL-33 was associated with susceptibility to OS in Han Chinese population.

Methods
=======

Study subjects
--------------

A total of 1,605 study subjects including 1,098 healthy controls and 507 OS patients were recruited from 3 clinical centers located in Xi\'an (Shaanxi Traditional Chinese Medicine Hospital, Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine and Honghui Hospital of Xi\'an Jiaotong University). All patients were diagnosed with OS based on histological and pathological evidence by at least two experienced pathologists. All healthy controls were identified by health screening and recruited from the same hospitals mentioned above. All subjects were Han Chinese individuals from the same geographic region of Xi\'an, China. This study has been approved by the Medical Ethics Committee of Xi\'an Jiaotong University. Informed consent forms were obtained from all participants. The characteristic information for all study subjects were summarized in Table [1](#T1){ref-type="table"}. No differences were identified for age, gender or family history between OS case and control groups.

SNP selection and Genotyping
----------------------------

SNPs in the gene region of the *IL-33* with minor allele frequencies (MAF) ≥ 0.01 based on 1000 genome data were extracted. Then, MAF ≥ 0.01 by pair-wise tagging and r[@B2] ≥ 0.8 were used as selection criteria for tag SNPs, and 18 tag SNPs were generated for genotyping. The information regarding the 18 tag SNPs is summarized in Supplemental Table [S1](#SM0){ref-type="supplementary-material"}. Genomic DNA was isolated from the peripheral blood using a Tiangen DNA extraction kit (Tiangen Biotech Co. Ltd, Beijing, China). Sequenom MassARRAY platform was utilized for SNP genotyping. Typer 4.0 was used for genotyping results processing. We randomly re-performed the analysis on 5% of the samples and found a concordance of 100%. The MAFs of these SNPs in our study subjects ranged from 0.039-0.484, and all of these SNPs were in Hardy-Weinberg equilibrium (HWE) in our controls (Supplemental Table [S1](#SM0){ref-type="supplementary-material"}). Power analyses were performed using GAS power calculator, and the results were showed in Ssupplemental Figure S1. As seen from this figure, 500 OS cases could achieve statistical power of 78.7% to detect a SNP with relative risk equal to 1.4 at α=0.05 level.

Statistics and bioinformatics analysis
--------------------------------------

HWE was tested for all SNPs by Haploview v4.2 [@B19]. Differences of multiple clinical and characteristic variables between cases and controls were examined by Student\'s *t* and χ^2^ tests. Genetic associations between selected SNPs and OS risk were tested using Plink [@B20]. The linkage disequilibrium (LD) structure was plotted using Haploview v4.2 [@B19]. Survival analyses, including Kaplan-Meier analysis and Cox model fitting for significant SNPs, were performed using R project (using "survival" and "survminer" packages) [@B21]. Bonferroni corrections were applied if necessary to address the problem of multiple comparisons. To examine the functional consequences of the significant SNP, we performed bioinformatics analyses using the GTEx [@B22] and the PolymiRTS Database [@B23]. The eQTL effects of significant SNPs on gene *IL-33* were investigated using gene expression data from multiple human tissues that were extracted from GTEx. The effects of an SNP on miRNA-mediated gene expression were evaluated using the PolymiRTS Database.

Results
=======

Single marker based association analyses
----------------------------------------

SNP rs1048274, which is located at 3\' untranslated region of *IL-33*, was identified to be significantly associated with the disease status of OS (Table [2](#T2){ref-type="table"}), and its significance was retained after Bonferroni correction (Table [2](#T2){ref-type="table"}). Our results showed that the minor allele (A) of this SNP had significant protective effect against OS (OR=0.75, *P*=1.53×10^-4^). The LD structure of our 18 selected tag SNPs is shown in Supplemental Figure [S2](#SM0){ref-type="supplementary-material"}, but there was no LD block which included the associated SNP of rs1048274. Furthermore, we examined the distribution of multiple clinical variables in the OS groups with different genotypes of rs1048274 (Table [3](#T3){ref-type="table"}). None of those variables were identified as significantly associated with any of the genotypes of rs1048274 within OS patients.

Survival analyses
-----------------

An overall survival plot for all of our OS patients stratified by genotypes of rs1048274 (AA, GA and GG groups) was made, and Kaplan-Meier analysis was conducted (Figure [1](#F1){ref-type="fig"}). Significant differences of survival curves were obtained (*P*=0.0072) between the three genotype groups. Compared to the GA and GG groups, OS patients with the AA genotype of rs1048274 had better survival rate. Next, we performed Kaplan-Meier analysis stratified by Enneking stages (Supplemental Figure [S3](#SM0){ref-type="supplementary-material"}-S5) and gender (Supplemental Figure [S6](#SM0){ref-type="supplementary-material"} and S7). The patterns of the survival curves for each stratification variable were similar to the overall survival curves. For all survival curves, OS patients with AA genotype had better survival rate, although this statistical difference was not very significant when the curves were stratified by gender (*P*=0.025 for male and*P*=0.13 for female).

A Cox model adjusted with multiple clinical variables was fitted (Figure [2](#F2){ref-type="fig"}) to the curves. The coding scheme is shown in Supplemental Table [S2](#SM0){ref-type="supplementary-material"}. Since the survival curves of the GG and GA groups were very similar to each other (Figure [1](#F1){ref-type="fig"}), we combined the two groups in the Cox model. The adjusted hazard ratio of SNP rs1048274 (AA group compared to GG+GA group) was 0.35 (with 95% confidence interval of 0.25-0.5). The two other variables, gender and Enneking stages, were also significant in our Cox model.

Bioinformatics analyses
-----------------------

Gene expression data of *IL-33* from 47 human tissues was extracted. The most significant eQTL finding for rs1048274 was identified in the esophagus (*P*=0.076 Supplemental Table [S3](#SM0){ref-type="supplementary-material"}). However, this hit failed to survive after Bonferroni correction. According to the genomic database from the University of California, Santa Cruz (<http://genome.ucsc.edu/>), rs1048274 acts as a 3\' untranslated region (3\' UTR) variant, which may affect microRNA binding. We used a free online tool (PolymiRTS Database) to examine the predicted target gain or loss in microRNA binding and found that the A allele of rs1048274 causes the loss of binding of microRNA/SNP target duplexes of two miRNAs (hsa-miR-543 and hsa-miR-570-3p) and *IL-33*. Comparatively, the G allele of rs1048274 maintains a stable microRNA-binding site at the 3\' UTR region of *IL-33*.

Discussion
==========

Previous GWAS have linked IL-33 to several disease states including asthma [@B24]-[@B25] and periodontal microbiota [@B26]. GWAS using European and Brazilian samples conducted by Koster et al. have shown that *IL-33* might contribute to susceptibility to the risk of OS. However, this evidence was weak because the significant SNP identified by this GWAS was located in the *GLDC* gene and was only linked with *IL-33* based on publicly available data on gene expressions. In addition, study conducted by Koster*et al.* was based on European populations, and the genetic structure of OS related SNPs of *IL33* was still unclear for Chinese population considering the differences in linkage disequilibrium structure between the two ethnic groups. To the best of our knowledge, the present study is the first one to identify the association of *IL33* with the risk of OS in Han Chinese population. Our study replicates and builds on this previous work by using samples with Chinese Han ancestry. In this study, we have identified SNP rs1048274 to be significantly associated with the disease status of OS. The minor allele of this SNP, the A allele, could significantly decrease the risk of OS by 25%. This SNP, located at the 3\' untranslated region of *IL-33*, was physically closer to *IL-33* compared to both rs3765555 and rs55933544, which were identified in the previous GWAS. SNP rs1048274 was missed by this previous GWAS. A potential reason might be its difference in the MAF (0.43 for East Asians and 0.32 for Europeans according to the 1000 Genome Project) and the LD structure around it between Chinese and European populations. In addition to its contribution to OS susceptibility, SNP rs1048274 was also associated with prognosis for OS patients. According to our survival analysis, OS patients with the AA genotype could, in general, exhibit significantly better survival rates compared to those with either the GG or GA genotypes. This pattern was not associated with the Enneking stages of OS or gender. Similar to its effect on OS susceptibility, the A allele of SNP rs1048274 has hazard ratio of 0.35 after adjustment for multiple clinical variables.

In the present study, we have identified that the A allele of SNP rs1048274 significantly increases the survival rate of OS patients compared to the G allele. Our bioinformatics analyses have shown that rs1048274\'s ancestral G allele is a very conserved miRNA binding site which binds miRNA and inhibits gene expression of *IL-33*. The A allele is likely to disrupt this binding site and thus increase its expression. Early studies have shown that IL-33 could promote type I antitumor immune responses through CD8+ T cells and NK cells [@B10],[@B11]. In other words, the protein product of the gene *IL-33* might be related to the inhibition of tumor cells, and therefore, a higher level of *IL-33* expression might be protective against OS. Although a systematic investigation of the expression levels of *IL-33* is out of the scope of this study, our findings could still provide some clues for the hypothesis stated above. Nevertheless, since the findings from our bioinformatics analyses were functional predictions based on computer algorithms, and no experimental data has been reported, we need to be careful when interpreting these findings.

With the rapid development of high-throughput sequencing technology, genetic association analysis provides an effective method for studying the molecular genetic mechanism of complex diseases, such as schizophrenia, but it is still unknown for us to understand the genetic risk and molecular mechanism of OS [@B27]-[@B36]. Despite our interesting findings on the association between rs1048274 and the susceptibility and prognosis of OS, this study suffered from several limitations. A major issue is that population stratification might be a potential confounder for our association signal. As a candidate gene based study, we did not have enough SNPs to perform some conventional approaches (such as principal component analysis) to address this problem. Nevertheless, we have applied some criteria to restrict the genetic background of our study subjects to minimize their genetic heterogeneity. Thus, due to the subject individuals from the same geographical area, although the potential population stratification cannot be completely excluded, our sampling strategy can effectively avoid significant population stratification to the greatest extent [@B37]-[@B42]. Another limitation is that this study is not a randomized clinical trial, thus selection bias might be present. OS patients and controls were not randomly selected individuals and our study subjects may not be a representative sample. To the best of our knowledge, the present study is the first one to identify an association signal for rs1048274 and OS susceptibility and its prognosis. Replication studies are needed in the future, especially those based on different ethnic populations.

In summary, we have showed strong evidence for association between SNP rs1048274 of *IL-33* and susceptibility to OS in the Chinese Han population. This SNP was also identified as significantly associated with the prognosis of OS in further analyses of OS patients. This is the first large-scale population based genetic report on polymorphisms of IL-33 using samples with Chinese ancestry. Thus, replication studies based on other populations as well as further investigations of the underlying mechanism responsible for these associations are still needed.
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###### 

Distributions of selected variables in all subjects

  Variables                   Subjects (N=1605)   Statistics   *P*-value      
  --------------------------- ------------------- ------------ -------------- ------
  Mean age, years (%)         21.08±6.1           21.12±5.8    *T*=-0.12      0.90
  ≤20                         318 (62.7)          700 (63.8)                  
  \>20                        189 (37.3)          398 (36.2)   χ^2^=0.12      0.73
  Gender (%)                                                                  
  Male                        261 (51.5)          563 (51.3)                  
  Female                      246 (48.5)          535 (48.7)   χ^2^= 0.0005   0.98
  Cancer family history (%)                                                   
  Yes                         158 (31.2)          333 (30.3)                  
  No                          349 (68.8)          765 (69.7)   χ^2^= 0.08     0.78
  Tumor location (%)                                                          
  Long tubular bones          408 (80.5)          \-                          
  Axial skeleton              99 (19.5)           \-           \-             \-
  Pathological fracture (%)                                                   
  Yes                         87 (17.2)           \-                          
  No                          420 (82.8)          \-           \-             \-
  Metastasis (%)                                                              
  Yes                         112 (22.1)          \-                          
  No                          395 (77.9)          \-           \-             \-
  Enneking stages (%)                                                         
  I                           47 (9.3)            \-                          
  II                          391 (77.1)          \-                          
  III                         69 (13.6)           \-           \-             \-

###### 

Results of single marker based association analyses

  CHR     SNP             POS           A1      F_A         F_U         χ^2^         *P*               OR
  ------- --------------- ------------- ------- ----------- ----------- ------------ ----------------- ----------
  9       rs1157505       6216240       G       0.265       0.262       0.043        0.84              1.02
  9       rs11791561      6216516       C       0.449       0.453       0.054        0.82              0.98
  9       rs72614080      6218595       T       0.274       0.279       0.071        0.79              0.98
  9       rs1891385       6219845       C       0.223       0.226       0.035        0.85              0.98
  9       rs143589217     6220187       A       0.048       0.047       0.031        0.86              1.03
  9       rs16924144      6221246       C       0.314       0.317       0.036        0.85              0.98
  9       rs183791076     6222545       G       0.052       0.053       0.004        0.95              0.99
  9       rs10975495      6223819       A       0.057       0.055       0.086        0.77              1.05
  9       rs1418385       6226295       T       0.476       0.472       0.058        0.81              1.02
  9       rs16924159      6229417       A       0.298       0.293       0.084        0.77              1.02
  9       rs189217453     6230731       T       0.050       0.048       0.092        0.76              1.06
  9       rs182211245     6230736       C       0.050       0.051       0.019        0.89              0.98
  9       rs117414011     6242939       C       0.071       0.076       0.256        0.61              0.93
  9       rs4742170       6242950       C       0.487       0.482       0.068        0.79              1.02
  9       rs79981454      6247232       C       0.042       0.038       0.391        0.53              1.13
  9       rs76864631      6248408       A       0.248       0.242       0.124        0.73              1.03
  9       rs10758751      6252044       C       0.074       0.077       0.064        0.80              0.96
  **9**   **rs1048274**   **6256292**   **A**   **0.414**   **0.486**   **14.340**   **1.53×10^-4^**   **0.75**

POS: position; A1: tested allele; F_A: allele frequency in cases; F_U: allele frequency in controls. Threshold of *P* value was 0.0028 (0.05/18). Significant results were highlighted in bold.

###### 

Association between genotypes of rs1048274 and several clinical variables within our OS subjects

                               Genotypes of rs1048274 (N=507)   Statistics   *P*                      
  ---------------------------- -------------------------------- ------------ ------------ ----------- ------
  Age in years, mean±sd        20.6±5.8                         21.4±6.2     20.8±6.0     *F*=0.03    0.87
  Gender (%)                                                                                          
  Male (N=261)                 43 (16.5)                        130 (49.8)   88 (33.7)                
  Female (N=246)               40 (16.3)                        124 (50.4)   82 (33.3)    χ^2^=0.02   0.99
  Tumor location (%)                                                                                  
  Long tubular bones (N=408)   62 (15.2)                        209 (51.2)   137 (33.6)               
  Axial skeleton (N=99)        21 (21.2)                        45 (45.5)    33 (33.3)    χ^2^=2.29   0.32
  Pathological fracture (%)                                                                           
  Yes (N=87)                   13 (14.9)                        47 (54.0)    27 (31.1)                
  No (N=420)                   70 (16.7)                        207 (49.3)   143 (34.0)   χ^2^=0.65   0.72
  Metastasis (%)                                                                                      
  Yes (N=112)                  18 (16.1)                        55 (49.1)    39 (34.8)                
  No (N=395)                   65 (16.5)                        199 (50.4)   131 (33.1)   χ^2^=0.11   0.95
  Enneking stages (%)                                                                                 
  I (N=47)                     11 (23.4)                        23 (48.9)    13 (27.7)                
  II (N=391)                   58 (14.8)                        199 (50.9)   134 (34.3)               
  III (N=69)                   14 (20.3)                        32 (46.4)    23 (33.3)    χ^2^=3.43   0.49
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